FDA Steps Up Alzheimer’s Initiatives, Plans October Stakeholders Meeting
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Drug treatments and biomarker development for Alzheimer’s disease are on the agenda of a meeting FDA expects to hold in October with neurological organizations, Janet Woodcock, the agency’s chief medical officer, said during a July 25 audio conference sponsored by Avalere.